Developer docs
API playgroundTry for free, no card

Search company profiles

IM HealthScience

Full company profile

uuid003d6cu

Namestring
IM HealthScience
Websiteurl
imhealthscience.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

IM HealthScience is a privately held, for-profit company founded in 2013, headquartered in Boca Raton, Florida, with 101–250 employees. According to its firmographic profile, the company develops products addressing overall health and wellness, including conditions described as having a high unmet medical need. The named leadership includes founder Fred Hassan and CFO Sarah Hassan, consistent with a founder-led, small/mid-cap health sciences firm.

The input data, however, contains a material discrepancy that limits further characterization. The website domain imhealthscience.com, as scraped, hosts Indonesian-language blog content about online slot gaming (PG Soft, Lucky Neko) and references the WADUK89 gambling platform. No health science products, pipeline information, technology stack, distribution channels, pricing, customer segments, partnerships, certifications, patents, or revenue figures are disclosed in the source material. As a result, the operational specifics of the business — its products, go-to-market model, revenue mechanics, and competitive positioning — cannot be verified from the supplied data. The remaining sections of this analysis reflect this evidence gap and should be treated accordingly.

Short descriptiontext

IM HealthScience is a privately held health and wellness company founded in 2013 and based in Boca Raton, Florida, that develops products for conditions with high unmet medical need. Its specific product portfolio, revenue model, and customer segments are not disclosed in the available data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
health and wellness, consumer health products, medical nutrition, wellness solutions, unmet medical need
Industry1 code
PRIMARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition
NAICS code1 code
  • Food (Health) Supplement Retailers456191
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Consumer Health Products
No data
Cost components5 values
Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IM HealthScience develops and sells products aimed at overall health and wellness, with an emphasis on conditions characterized by high unmet medical need. The company focuses on bringing health products to market for underserved wellness and medical needs among consumers.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Health and wellness products
CategoryConsumer Health Products
Description

Consumer-facing health and wellness products developed to address overall health and wellness needs, with particular focus on conditions characterized by high unmet medical need. Intended for individual consumers seeking targeted health solutions.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers8 records
1Metagenics
TypeDirect peer
Description

Science-based medical foods and supplements company sold through healthcare practitioners, with strong GI and cardiometabolic positions. Comparable in positioning clinically validated nutrition products for specific medical conditions.

2Perrigo Company
TypeBroad incumbent
Description

Global consumer self-care company with a major OTC and specialty GI/specialty franchise (e.g., gastroenterology, nutrition). Comparable to IM HealthScience's branded health-and-wellness positioning in self-care categories.

3Standard Process
TypeEmerging player
Description

Whole-food supplements and clinical nutrition company sold primarily through healthcare practitioners. Comparable channel and clinician-marketing approach, though narrower in condition-specific positioning.

4Salix Pharmaceuticals (Bausch Health)
TypeBroad incumbent
Description

Established GI specialty pharma franchise within Bausch Health, with a sales force focused on gastroenterologists. Comparable go-to-market model targeting the same prescriber base as a specialty health brand.

5Nestlé Health Science
TypeBroad incumbent
Description

Global consumer health and medical nutrition company with a broad portfolio across GI, metabolic, and pediatric nutrition. Directly comparable to IM HealthScience as a science-led branded health and wellness platform targeting condition-specific consumer needs.

6Ironwood Pharmaceuticals
TypeDirect peer
Description

Specialty GI company behind LINZESS for IBS-C/CIC, focused on branded prescription and consumer GI therapies. Closest US-listed analog to IM HealthScience's bowel-disorder specialty positioning and physician-detailing model.

7Prestige Consumer Healthcare
TypeBroad incumbent
Description

OTC and consumer healthcare brand company with a portfolio across GI, cough/cold, and women's health. Comparable as a branded OTC health platform with similar distribution and shelf-space dynamics.

8Allergan / AbbVie (GI franchise)
TypeBroad incumbent
Description

Major pharma with a substantial gastroenterology specialty franchise (e.g., LINZESS co-promote, IBS/inflammatory bowel drugs). Comparable in targeting the same GI specialty channel and unmet-need conditions.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IM HealthScience

Consumer Health Productsimhealthscience.com

IM HealthScience is a privately held health and wellness company founded in 2013 and based in Boca Raton, Florida, that develops products for conditions with high unmet medical need. Its specific product portfolio, revenue model, and customer segments are not disclosed in the available data.

What IM HealthScience does

IM HealthScience is a privately held, for-profit company founded in 2013, headquartered in Boca Raton, Florida, with 101–250 employees. According to its firmographic profile, the company develops products addressing overall health and wellness, including conditions described as having a high unmet medical need. The named leadership includes founder Fred Hassan and CFO Sarah Hassan, consistent with a founder-led, small/mid-cap health sciences firm.

The input data, however, contains a material discrepancy that limits further characterization. The website domain imhealthscience.com, as scraped, hosts Indonesian-language blog content about online slot gaming (PG Soft, Lucky Neko) and references the WADUK89 gambling platform. No health science products, pipeline information, technology stack, distribution channels, pricing, customer segments, partnerships, certifications, patents, or revenue figures are disclosed in the source material. As a result, the operational specifics of the business — its products, go-to-market model, revenue mechanics, and competitive positioning — cannot be verified from the supplied data. The remaining sections of this analysis reflect this evidence gap and should be treated accordingly.

IM HealthScience firmographics

Firmographics
Name
IM HealthScience
Website
https://imhealthscience.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
IM HealthScience is a privately held health and wellness company founded in 2013 and based in Boca Raton, Florida, that develops products for conditions with high unmet medical need. Its specific product portfolio, revenue model, and customer segments are not disclosed in the available data.
Ownership category
akta.pro rank

IM HealthScience industry classification

Industry
Product category
Consumer Health Products
NAICS
Food (Health) Supplement Retailers (456191)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

Keywords

  • Health and wellness
  • Consumer health products
  • Medical nutrition
  • Wellness solutions
  • Unmet medical need

Where IM HealthScience is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Markets served

IM HealthScience business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

IM HealthScience product offering

Product offering

Core offering

IM HealthScience develops and sells products aimed at overall health and wellness, with an emphasis on conditions characterized by high unmet medical need. The company focuses on bringing health products to market for underserved wellness and medical needs among consumers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Health and wellness products Consumer-facing health and wellness products developed to address overall health and wellness needs, with particular focus on conditions characterized by high unmet medical need. Intended for individual consumers seeking targeted health solutions.

Companies that use IM HealthScience

Customer profile

Ideal customer profiles1 record

IM HealthScience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

IM HealthScience partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

IM HealthScience competitors and assessment

Company assessment

Direct peers

  • Metagenics: Science-based medical foods and supplements company sold through healthcare practitioners, with strong GI and cardiometabolic positions. Comparable in positioning clinically validated nutrition products for specific medical conditions.
  • Ironwood Pharmaceuticals: Specialty GI company behind LINZESS for IBS-C/CIC, focused on branded prescription and consumer GI therapies. Closest US-listed analog to IM HealthScience's bowel-disorder specialty positioning and physician-detailing model.

Broad incumbents

  • Perrigo Company: Global consumer self-care company with a major OTC and specialty GI/specialty franchise (e.g., gastroenterology, nutrition). Comparable to IM HealthScience's branded health-and-wellness positioning in self-care categories.
  • Salix Pharmaceuticals (Bausch Health): Established GI specialty pharma franchise within Bausch Health, with a sales force focused on gastroenterologists. Comparable go-to-market model targeting the same prescriber base as a specialty health brand.
  • Nestlé Health Science: Global consumer health and medical nutrition company with a broad portfolio across GI, metabolic, and pediatric nutrition. Directly comparable to IM HealthScience as a science-led branded health and wellness platform targeting condition-specific consumer needs.
  • Prestige Consumer Healthcare: OTC and consumer healthcare brand company with a portfolio across GI, cough/cold, and women's health. Comparable as a branded OTC health platform with similar distribution and shelf-space dynamics.
  • Allergan / AbbVie (GI franchise): Major pharma with a substantial gastroenterology specialty franchise (e.g., LINZESS co-promote, IBS/inflammatory bowel drugs). Comparable in targeting the same GI specialty channel and unmet-need conditions.

Emerging players

  • Standard Process: Whole-food supplements and clinical nutrition company sold primarily through healthcare practitioners. Comparable channel and clinician-marketing approach, though narrower in condition-specific positioning.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

IM HealthScience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IM HealthScience leadership team

Management profile

Number of profiles

Profiles2 records

IM HealthScience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IM HealthScience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IM HealthScience

What does IM HealthScience do?

IM HealthScience develops and sells products aimed at overall health and wellness, with an emphasis on conditions characterized by high unmet medical need. The company focuses on bringing health products to market for underserved wellness and medical needs among consumers.

When was IM HealthScience founded?

IM HealthScience was founded in 2012. It employs 51 to 100 people.

Where is IM HealthScience based?

IM HealthScience is headquartered in Boca Raton, United States, in the North America region.

Who are IM HealthScience's main competitors?

Direct peers on record are Metagenics and Ironwood Pharmaceuticals. Broad incumbents are Perrigo Company, Salix Pharmaceuticals (Bausch Health), Nestlé Health Science, Prestige Consumer Healthcare and Allergan / AbbVie (GI franchise). Standard Process is listed as an emerging player.

Does IM HealthScience have an API?

No public API is recorded for IM HealthScience.

What industry is IM HealthScience in?

IM HealthScience's product category is Consumer Health Products. Its primary akta.pro industry code is CRADAGAB, Vitamins & Minerals (Single Nutrients). Its NAICS code is 456191 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire36-Month Post-Marketing Surveillance Report For FDgard®, Now Available For Review At The American College Of Gastroenterology (ACG) E-Poster WebsiteIM HealthScience announced the availability of a 36-month post-marketing safety surveillance report for FDgard on the American College of Gastroenterology e-poster website, covering approximately one million patients from July 2016 to July 2019. The surveillance found no serious adverse events reported and a low rate of non-serious adverse events at 0.019%, with 205 events received from 179 patients. The findings were peer-reviewed and presented at the ACG Annual Scientific Meeting in October 2020.PR NewswireAcquisition of IM HealthScience CompletedNestlé Health Science completed the acquisition of IM HealthScience and its sister company Physician's Seal on September 1, 2020. IM HealthScience, a privately held company founded in 2010 and based in Boca Raton, Florida, is the innovator of digestive health brands including IBgard, FDgard, Fiber Choice, and REMfresh. The acquiring company stated that this transaction will allow the four acquired brands to greatly expand their marketplace footprint.PR NewswireUnprecedented 3-Year Safety Data Unveiled At Digestive Disease Week (DDW) Indicates No Pattern Of Heartburn With IBgard®, An Advanced Technology Peppermint Oil, Contrary To Heartburn Issues With OlderIM HealthScience announced that its 36-month post-marketing safety surveillance study (IBSSU36) for IBgard showed no pattern of heartburn or anal burning among an estimated 2.4 million patients who used the product between October 2015 and September 2018, in contrast to older liquid-filled peppermint oil formulations that reported adverse event rates of 26 to 29.7%. The peer-reviewed e-poster was presented at Digestive Disease Week, with lead author Dr. Brian Lacy of the Mayo Clinic confirming no serious adverse events were reported during the surveillance period.PR NewswireIn A Peer-Reviewed Article In A Leading Gastroenterology Journal, Nonprescription FDgard® Is Added To Treatment Algorithm For The Management Of Functional Dyspepsia (FD)IM HealthScience announced that its nonprescription medical food FDgard® was included by name in a peer-reviewed article published in the February 2020 issue of Gastroenterology and Hepatology, adding it to a treatment algorithm for Functional Dyspepsia (FD). The inclusion was supported by clinical data from the FDREST randomized controlled trial, which demonstrated statistically significant rapid reduction of FD symptoms within 24 hours in patients taking FDgard. FDgard is the only nonprescription product included in the algorithm, and there are currently no FDA-approved drugs for FD, a condition affecting up to 10–24% of the population.PR NewswireFirst-Ever, 36-Month Real-World, Post-Marketing Surveillance Study For IBgard®, A Nonprescription Product For Irritable Bowel Syndrome, Now Peer-Reviewed and Now Accepted For Poster Presentation At UpIM HealthScience announced that its 36-month post-marketing surveillance study (IBSSU36) for IBgard has been peer-reviewed and accepted for poster presentation at Digestive Disease Week 2020, with favorable safety results from the longest-running study of its type. The study, covering approximately 2.4 million individual patients who used the product between October 2015 and September 2018, reported no serious adverse events and no significant pattern of non-serious adverse events or heartburn. Notably, the absence of heartburn is significant given that conventional peppermint oil preparations are known to cause this side effect, which is particularly problematic for IBS patients who experience heartburn at four times the rate of the general population.PR NewswireIn The Longest-Running Post-Marketing Surveillance Study Of Its Type, Data At 24 Months On FDgard®, Presented At The American College Of Gastroenterology (ACG) Annual Meeting, Confirms Excellent SafetIM HealthScience announced favorable 24-month post-marketing safety surveillance data for FDgard, a nonprescription medical food for Functional Dyspepsia, presented at the American College of Gastroenterology Annual Meeting. The study, covering an estimated 558,300 patients over a two-year monitoring period from July 2016 to July 2018, reported no serious adverse events and an extremely low non-serious adverse event rate of 0.0265%, reconfirming the product's previously established excellent safety and tolerability profile. The findings also reinforced prior clinical trial data demonstrating the efficacy of FDgard's patented solid-state microsphere formulation of caraway oil and l-Menthol in managing Functional Dyspepsia, a condition affecting an estimated one in six American adults.PR NewswireFor The Third Year In A Row, Gastroenterologists Nationwide Endorse Nonprescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion(i)) (ii)IM HealthScience announced that its nonprescription medical food FDgard was named the #1 gastroenterologist-recommended herbal product for Functional Dyspepsia for the third consecutive year, according to a ProVoice survey conducted by IQVIA in June 2019 among 202 U.S. gastroenterologists, with 67% of recommendations. The survey was validated at a 99% confidence level, and the results were published alongside clinical data from the landmark FDREST randomized controlled trial demonstrating statistically significant rapid reduction of FD symptoms within 24 hours. FDgard is available over-the-counter at major retailers nationwide and online, with the company citing the product as addressing a high unmet medical need since no approved prescription drugs exist for Functional Dyspepsia.PR NewswireIn the Longest-Ever String of Yearly Surveys on Gastroenterologists' Preferences for Recommending Products for IBS, IBgard Continues to Widen its Already Pre-Eminent "#1 Recommended"(1) StatusIM HealthScience announced that its nonprescription medical food IBgard has been confirmed as the #1 gastroenterologist-recommended peppermint oil product for irritable bowel syndrome for the fifth consecutive year, with an 80% share of physician recommendations in a nationwide survey. The company highlighted clinical studies supporting the product's efficacy, safety, and tolerability, citing a 36-month post-marketing surveillance study and peer-reviewed research published in Digestive Diseases and Sciences. IBgard, which uses a patented triple-coated microsphere technology for targeted delivery of peppermint oil to the small intestine, has been on the U.S. market since 2014.PR NewswireFirst-Ever 36 Month Real-World, Post-Marketing Surveillance Study Confirms The Excellent Safety And Tolerability Profile Of IBgard®, A Non-Prescription Product For IBSIM HealthScience announced favorable results from the IBSSU36 post-marketing surveillance study of IBgard, covering approximately 2.48 million patients from October 2015 to October 2018. The study found no serious adverse events and no significant pattern of non-serious adverse events, including notably no heartburn pattern that distinguishes IBgard from conventional peppermint oil products. The 36-month data reaffirms the product's previously established favorable safety and tolerability profile.PR NewswireFor The Fourth Year In A Row, U.S. Gastroenterologists Endorse Clinically Studied, Nonprescription IBS Product, IBgard®, By An Overwhelming MarginIM HealthScience announced results of a nationwide ProVoice survey by IQVIA showing that IBgard, their peppermint oil-based medical food for irritable bowel syndrome, was endorsed as the #1 gastroenterologist-recommended peppermint oil product for the fourth consecutive year. The survey, conducted among 200 U.S. gastroenterologists in September-October 2018, validated the endorsement claim at a 99 percent confidence level, with over 10,000 healthcare practitioners and approximately one million patients estimated to have used the product since its 2014 launch. Clinical studies including IBSREST, IBSSU24, and IBSACT have demonstrated the product's efficacy in reducing eight hallmark IBS symptoms with no pattern of heartburn reported.